Calidi Biotherapeutics, INC Form 4 insider transactions

Director Leftwich Scott acquired 67,187 shares of Calidi Biotherapeutics common stock on June 28, 2024, increasing their total holdings to 560,873 shares.

Director James A. Schoeneck of Calidi Biotherapeutics, Inc. reports acquisition of 79,687 shares of common stock through a restricted stock unit (RSU) grant.

Director Alan R. Stewart acquired 73,437 shares of Calidi Biotherapeutics common stock on June 28, 2024, increasing his holdings to 154,087 shares.

Director Scott Leftwich reports acquiring 23,783 shares of Calidi Biotherapeutics common stock through a grant of restricted stock units.

Director James A. Schoeneck reports acquisition of 28,207 shares of Calidi Biotherapeutics common stock through a grant of restricted stock units.

Director Alan R. Stewart reports acquiring 25,995 shares of Calidi Biotherapeutics common stock through a grant of restricted stock units.

Calidi Biotherapeutics CEO Allan Camaisa was granted 40,000 incentive stock options on June 17, 2024, under the company's 2023 Equity Incentive Plan.

Boris Minev, Interim Chief Medical Officer of Calidi Biotherapeutics, received stock options and granted a limited power of attorney for SEC filings.

Wendy Pizarro Campbell, Chief Admin. and Legal Officer of Calidi Biotherapeutics, was granted stock options to purchase 100,000 shares of common stock at an exercise price of $0.195 per share.

Andrew Jackson, CFO of Calidi Biotherapeutics, was granted 300,000 stock options on June 17, 2024, at an exercise price of $0.195.

James A. Schoeneck, a director at Calidi Biotherapeutics, exercised warrants to acquire common stock and new warrants, as part of an inducement offer.

James Schoeneck, a director of Calidi Biotherapeutics, acquired 375,000 shares of common stock and associated warrants through a recent public offering.